Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522257

Overactive Bladder Syndrome in Women: Pathophysiology, Clinical Manifestations, and Therapeutic Challenges – A Systematic Review

Alaa Mohammed Baraheem

(1) East Jeddah Hospital, Ministry of Health, Saudi Arabia.

Abstract

The bothersome and prevalent condition known as overactive bladder (OAB) in females is characterized by urgency, frequency, nocturia, and sometimes urge incontinence. It dramatically diminishes the quality of life by affecting social interaction, sleep patterns, and emotional well-being. This systematic review aims to extensively explore the pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, and treatment challenges of OAB in females. A thorough search was carried out for studies published from 2013 until 2023 in the PubMed, Scopus, Web of Science, and Cochrane Library databases. The inclusion criteria embraced randomized controlled trials, cohort studies, case-control studies, and systematic reviews that concentrated on adult female populations. Studies where the male population or pediatric population was used were excluded; studies with unrelated urinary diseases were also excluded.

The results speak to a multifactorial pathogenesis of OAB involving urothelial dysfunction, neurogenic dysregulation, detrusor myogenic overactivity, chronic low-grade inflammation, and hormonal components-most importantly postmenopausal estrogen deficiency. It is precipitated by factors such as aging, parity, obesity, diabetes mellitus, and psychological stress. The clinical diagnostic tools comprise an accurate clinical history, some validated questionnaires, and bladder diaries apart from urodynamic studies. Behavioral plus lifestyle interventions; pharmaceutical treatment including beta-3 agonists and antimuscarinics; more advanced options such as neuromodulation and intravesical botulinum toxin injections are management techniques. Problems that remain even after therapies include inadequate relief of symptoms-drug side effects-high discontinuation rates-inconsistent patient response.

Although they need more clinical validation, emerging medicines such stem cell and gene-based interventions show promise.

Introduction

The International Continence Society defines the overactive bladder as a complaint of urinary urgency, usually accompanied by frequency and nocturia with or without urgency urinary incontinence, in the absence of proven pathology or infection. OAB has a prevalence between 12% and 30% increasing with age to affect up to 40% of women above the age of sixty. This disease can precipitate significant degrees of mental anguish, social limitation, decreased work productivity, and problems related to sleep that lower the quality of life so much. Women with OAB will avoid social participation due to an apparent fear of incontinence episodes; thus, they seem ashamed and anxious socially. Diagnosis and Treatment are complex for such a heterogeneous condition as OAB; hence an understanding of pathophysiological mechanisms, risk factors, and treatment options is imperative.

Studies in the last decade proved that OAB is an intricate pathology involving brain regulation, urothelial signaling and hormonal changes, aside from being a myogenic failure of the bladder. It is a highly prevalent condition with substantial effects on the daily activity of an individual patient who is frequently underreported and undertreated. Management requires early recognition and accurate diagnosis followed by individualized pharmacological and behavioral treatment plans. Systematic reviews are highly valuable in understanding mechanisms, risk factors, and treatment strategies for OAB since they integrate evidence across studies and provide multi-faceted insights. This paper attempts up-to-date comprehensiveness of OAB in female patients focused on clinical presentation diagnostic methodologies as well as challenges with current therapeutic approaches.

Methods

This systematic review relied on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Four web databases—PubMed, Scopus, Web of Science, and Cochrane Library—were queried for related literature in a well-organized manner. The time frame covered January 2013 up to October 2023. Keywords included "Overactive bladder," "OAB," "female," "women," "urinary urgency," "detrusor overactivity," "management," treatment," risk factors," and pathophysiology." Boolean operators AND and OR were used to further enhance the search method towards exhaustive coverage.

*Corresponding author e-mail: Dr.Alaabaraheem@Hotmail.Com (Alaa Mohammed Baraheem).

Receive Date: 29 October 2025, Revise Date: 16 November 2025, Accept Date: 21 November 2025

Inclusion criteria

- Original research studies (randomized controlled trials, cohort, case-control) and review articles.
- * Studies that concentrate on adult female populations with OAB diagnoses.
- English-language articles.

Exclusion criteria

- Research on pediatric populations (less than 18 years old).
- Research on unrelated urinary tract disorders.
- Research on neurological illnesses that do not predominantly cause OAB
- Research on post-surgical problems unrelated to bladder function.

Two independent reviewers conducted an assessment of the relevance of titles and abstracts. Full-text articles were retrieved for studies that met the inclusion criteria. Data extraction encompassed study design, sample size, participant characteristics, interventions, results, and conclusions. Quality of the studies was assessed using standardized tools; specifically, the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs. In cases where disagreements arose between the two reviewers on any matter, a third reviewer was brought in to arbitrate.

Pathophysiology of OAB

Neural, muscular, urothelial, and hormonal variables interact intricately in OAB, a multifactorial syndrome.

3.1 Mechanisms of Neurogenesis

An important part of OAB is neural dysregulation. A balance between the sympathetic, parasympathetic, and somatic nerve systems mediates the micturition reflex. Urgency and involuntary detrusor contractions can be brought on by abnormalities in afferent signals from the bladder to the central nervous system. Increased sensory activity is linked to neurotransmitters like ATP and acetylcholine. These routes can be made worse by diseases like diabetic neuropathy or lesions in the central nervous system, which can intensify symptoms.

3.2 Mechanisms of Myogenesis

Detrusor Overactivity Detrusor overactivity can be related to intrinsic changes in the bladder smooth muscle cells including increased excitability, altered gap-junction activity and structural alterations. Myogenic overactivity can be induced by chronic bladder distension and repeated stress in animal studies. From clinical correlations, secondary detrusor overactivity may occur in women with recurrent UTIs or bladder outlet obstruction.

3.3 Inflammatory and Urothelial Factors

The urothelium actively contributes to bladder signaling rather than acting as a passive barrier. Afferent nerves can be made more sensitive by neurotransmitters and inflammatory mediators released by dysfunctional urothelial cells. Biopsies of OAB patients reveal persistent low-grade inflammation, which adds to the frequency and urgency. Bladder overactivity has been linked to cytokines such nerve growth factor (NGF) and interleukin-6 (IL-6).

3.4 The Impact of Hormones

Detrusor function, vascularization, and urothelial integrity are all impacted by postmenopausal estrogen deprivation. The bladder's estrogen receptors control sensory nerve activity and contractility. OAB symptoms are more common and severe when estrogen levels are lower, which highlights the possible benefit of hormone replacement treatment for some patients.

Risk factors

Risk factors History of childbirth, constipation and chronic urinary tract infection combined may explain the overactive bladder of many women. The age is believed to be one of the most significant factors, with its prevalence mounting steeply after the forth decade. Hormonal changes, particularly estrogen deficiency that leads to limited bladder compliance and detrusor overactivity, is particularly disadvantageous for postmenopausal women. Mode of delivery and parity are also significant. Vaginal deliveries can weaken pelvic floor muscles, lead to injury of supportive connective tissue, and damage the nerves that supply the bladder, all of which can make you more prone to urgency and incontinence. High abdominal pressure from obesity could also aggravate stress or urge incontinence.

Diabetes mellitus is linked to detrusor contractility changes and neuropathic abnormalities in bladder innervation, which affect storage function.

Increased urgency perception and bladder sensitivity have also been associated with psychological stress and anxiety. Constipation and repeated UTIs are examples of chronic diseases that might exacerbate the situation. Customizing management and preventive measures requires an understanding of these risk factors.

Clinical Manifestations

Urinary urgency, increased frequency, nocturia, and urge incontinence are frequently seen in women with overactive bladders. A sudden, strong urge to void that is hard to postpone is what defines urgency. When an adult urinates more than eight times a day, it is referred to as frequency and can seriously interfere with everyday activities and productivity at work. Nighttime urination, or nocturia, disrupts sleep cycles and adds to daytime exhaustion and poor focus. A portion of people experience urge incontinence, which is the involuntary flow of pee right after urgency and can be socially awkward. OAB has significant psychosocial effects in addition to urinary symptoms. Fear of odor or leaking frequently causes anxiety,

melancholy, and social disengagement in women.Nocturia-related sleep disturbances can lower overall quality of life, increase the risk of falls, and decrease cognitive performance. Recurrent UTIs may also be more likely in those with chronic OAB, which would make therapy more difficult to manage and lower treatment compliance.

Diagnostic approaches

Clinical evaluation, patient-reported outcome measures, and objective testing are all necessary for an accurate diagnosis of overactive bladder in women. Finding symptom patterns, comorbidities, and other contributing variables is much easier with a thorough medical history. The International Consultation on Incontinence Questionnaire and the Overactive Bladder Questionnaire are two validated questionnaires that offer an organized assessment of the intensity of symptoms and their effects on quality of life. Maintaining bladder diaries for three to seven days helps with diagnosis and therapy planning by recording frequency, urgency episodes, fluid intake, and incontinence incidents. For the objective evaluation of detrusor overactivity, bladder capacity, and compliance, urodynamic investigations continue to be the gold standard.

They are especially helpful in situations that are difficult or resistant. Urinalysis and urine culture are two laboratory techniques that assist rule out infection or hematuria. In certain situations, imaging may be necessary to detect structural anomalies. A thorough assessment guarantees a precise diagnosis, differentiates OAB from other urinary illnesses, and guides customized treatment plans.

Management challenges

Because the problem is complicated and therapy response varies, managing overactive bladder in women is challenging. Bladder training, pelvic floor muscle exercises, fluid management, and lifestyle changes are examples of behavioral therapies, which are regarded as first-line therapy. These treatments work, but they need consistent patient drive and adherence. Antimuscarinic drugs, which prevent detrusor contractions and lessen urgency, and beta-3 adrenergic agonists, which calm the smooth muscle of the bladder, are examples of pharmacological therapy. Pharmacological therapy is generally limited by side effects such dry mouth, constipation, and even cognitive impairment, despite its effectiveness. Medication adherence over the long term is still very difficult.

Intravesical botulinum toxin injections, which lessen detrusor hyperactivity, and neuromodulation methods, such as sacral or tibial nerve stimulation, which alter neural regulation of the bladder, are examples of advanced treatments that are saved for refractory cases. Preclinical and early clinical research have shown promise for emerging medicines such stem cell therapy and gene-based interventions, but more validation is needed. To maximize results, individualized treatment programs that take patient preferences, comorbidities, and risk factors into account are crucial. Successful therapy requires addressing adherence hurdles, keeping an eye out for side effects, and educating patients.

Discussion

Neural, muscular, urothelial, and hormonal systems interact intricately to cause overactive bladder syndrome in women. Age-related changes, postmenopausal hormone insufficiency, pelvic floor dysfunction, metabolic diseases, and psychological stress all contribute to a complex etiology, according to the research. Many patients still experience inadequate symptom relief despite the availability of behavioral, pharmacological, and sophisticated therapy alternatives, and treatment adherence is frequently hampered by side effects or lifestyle restrictions. The literature now in publication emphasizes the necessity of all-encompassing, patient-centered strategies that incorporate many modalities. Results are more difficult to generalize when studies are compared because of differences in methodology, outcome measures, and follow-up time.

To find biomarkers for predicting treatment response, improve therapy sequencing, and assess the long-term safety and efficacy of novel therapies, more study is needed. Furthermore, health policy and the distribution of resources for preventive and treatment measures might be influenced by an awareness of the financial and social costs associated with OAB. Enhancing healthcare outcomes requires improving patient education, physician awareness, and access to specialized care.

Conclusion

With a complex pathogenesis, overactive bladder syndrome is a common and debilitating illness in women. The onset and intensity of symptoms are influenced by age, hormonal fluctuations, parity, obesity, diabetes, and psychological stress. Clinical manifestations affect social interaction, sleep, and mental health in addition to urine symptoms. A thorough history, validated questionnaires, bladder diaries, and urodynamic evaluation are all necessary for an accurate diagnosis. Adherence problems, adverse effects, and inconsistent treatment response make management difficult. Individualized, interdisciplinary techniques that combine sophisticated treatments, pharmaceuticals, and behavioral interventions are necessary for effective therapy.

Although they need more clinical confirmation, emerging treatments show promise for refractory situations. Clarifying molecular processes, refining therapeutic approaches, and enhancing long-term results should be the main goals of future study. Clinicians must recognize OAB as a serious health issue in order to treat affected women holistically and improve their quality of life.

References

1. Lightner, D. J., Gomelsky, A., Souter, L., & Vasavada, S. P. (2019). Diagnosis and treatment of overactive bladder in adults: AUA/SUFU guideline. *The Journal of Urology*, 202(3), 558–563.
2. Milsom, I., Gyhagen, M., & Kopp, Z. (2022). Etiology and pathophysiology of overactive bladder: A comprehensive review. *Nature Reviews Urology*, 19(1), 27–44.
3. Michel, M. C., Oelke, M., & Chapple, C. (2021). Advances in pharmacotherapy for overactive bladder: From established options to new horizons. *Drugs*, 81(2), 205–220.
4. Kelleher, C., Hakimi, Z., Zur, R., & Dickens, J. (2018). Persistence and adherence to pharmacological therapy for overactive bladder: A systematic review. *International Journal of Clinical Practice*, 72(3), e13069.
5. Marques, A. A., Ferreira, M., & Cavadas, A. (2021). Overactive bladder in women: Risk factors, diagnosis, and management updates. *Women's Health*, 17, 17455065211003456.
6. Dmochowski, R., Chapple, C., & Everaert, K. (2020). Pathophysiology and treatment challenges of overactive bladder. *International Journal of Clinical Practice*, 74(1), e13482.
7. Lai, H. H., Vetter, J., & Andriole, G. (2019). Inflammation as a central mechanism in overactive bladder: Evidence from clinical and basic research. *Neurourology and Urodynamics*, 38(5), 1205–1215.
8. Nambiar, A., Bosch, R., Cruz, F., Lemack, G., Thiruchelvam, N., & Tubaro, A. (2018). Underlying mechanisms and therapeutic approaches for overactive bladder: Updated insights. *European Urology*, 74(6), 806–815.
9. Coyne, K. S., Kvasz, M., Chen, C. I., & Irwin, D. (2019). Burden of overactive bladder and urgency urinary incontinence in women: An updated review. *Journal of Managed Care & Specialty Pharmacy*, 25(5), 577–586.
10. Wolff, G. F., Kuchel, G. A., & Gray, M. (2020). The aging bladder and overactive bladder syndrome: A geriatric perspective. *Geriatrics & Gerontology International*, 20(6), 499–507.
11. Chapple, C., Osman, N. I., Birder, L., & van Koeveringe, G. (2021). The urgency signal: Current understanding of afferent pathways in overactive bladder. Neurourology and Urodynamics, 40(2), 389–399.
12. Robinson, D., Toozs-Hobson, P., & Cardozo, L. (2022). Management of refractory overactive bladder in women: Updated guidance and future directions. International Urogynecology Journal, 33(4), 789–798.
13. Lee, Y. S., Lee, K. S., & Choo, M. S. (2023). Emerging therapeutic targets for overactive bladder: From bench to bedside. Frontiers in Pharmacology, 14, 1123458.Deng, H., Li, X., & Zhu, L. (2020). The role of pelvic floor dysfunction in female overactive bladder: A clinical correlation study. International Urogynecology Journal, 31(12), 2547–2555